07:00 , Oct 18, 2012 |  BC Innovations  |  Targets & Mechanisms

Black mamba takes away pain

A French team has identified a pair of peptides, mambalgin-1 and mambalgin-2, from black mamba venom that could be useful for treating pain. 1 The peptides, which inhibit a class of acid-sensing ion channels on...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Flamel, Theralpha deal

The companies partnered to co-develop a controlled-release formulation of Theralpha's THA902 to treat pain. Flamel will contribute its Medusa nanogel polymer drug delivery technology, while Theralpha will use its Acid Sensing Ion Channels (ASICs) technology...
02:23 , Mar 7, 2007 |  BC Extra  |  Financial News

PainCeptor raises C$24.4 million

Neurology company PainCeptor (Montreal, Quebec) raised C$24.4 million (US$20.8 million) in a series B round. Investors included Desjardins Venture Capital; CDP Capital; T2C2/Bio 2000; Business Development Bank of Canada; and Lothian Partners. PainCeptor has two...
07:00 , Apr 5, 2004 |  BioCentury  |  Tools & Techniques

The double-barreled approach

Newly formed PainCeptor Pharma Corp. brings together two small Canadian pain companies, each of which was focused on a different target. NeuroCeptor Inc., a spinout from Queens University, was studying the role of neurotrophins, specifically...
08:00 , Mar 29, 2004 |  BC Week In Review  |  Company News

NeuroSearch, PainCeptor deal

The companies will conduct research on treating chronic pain with a focus on Acid Sensing Ion Channels (ASIC). They will identify compounds that block ASICs and the sensation of pain. PainCeptor will finance NEUS's research...
08:00 , Mar 29, 2004 |  BioCentury  |  Finance

Ebb & Flow

While the IPOs sails drooped in the U.S., Basilea (SWX:BSLN) - one of Europe's leading spinout companies - made it to market last week and commanded a market cap of more than a half a...
08:00 , Mar 22, 2004 |  BC Extra  |  Financial News

PainCeptor raises C$23 million

PainCeptor (Montreal, Quebec) raised C$23 million (US$17.2 million) in a private round led by CDP Capital. Other investors included the Business Development Bank of Canada; Desjardins; Canadian Medical Discoveries Fund; T2C2/ S*BIO 2000; MDS Capital;...